NTT Expands Its Data Center Footprint By 20%
1.9.2021 11:00:00 EEST | Business Wire | Press release
NTT Ltd.’s Global Data Centers division, a Leader in the IDC MarketScape Worldwide Data Center Colocation and Interconnection Services 2021 Vendor Assessment1, provides a full stack of ICT services and continues to expand its global data center footprint by 20% to build a connected future that will benefit enterprise and hyperscale clients around the world.
NTT operates data centers across Europe, North America, Africa, and Asia, including a major presence in India. It delivers and operates global interconnected data centers with cross regional data center networks through key markets such as London, Singapore, Tokyo, and Virginia in North America. Its expansions in data center services provide increased data center capacity and network connectivity across all geographies, including:
- Americas:
In 2020/21, three new data center campuses were opened in Hillsboro, OR, Santa Clara, CA, and Chicago, IL, in addition to expansion in Ashburn, VA. NTT’s 47-acre (approx. 190,000m2) Hillsboro campus features five data centers with 126MW of planned IT load and Subsea Connect, a trans-pacific network connectivity service that provides connectivity between Hillsboro, Oregon and Tokyo, Japan using NTT’s Pacific Crossing (PC-1) subsea cable system. The Phoenix, AZ campus will open in early 2022 and be the seventh US data center campus. NTT Phoenix PH1 will add 36MW of IT load capacity and is the first of seven planned data centers on the 240MW campus.
- EMEA:
In the past year, NTT has opened new data center buildings in Amsterdam in the Netherlands, and Munich and Frankfurt in Germany, continuing its position as the number one data center provider in the German market. In the UK, the new flagship London 1 Data Center opened in December and, when fully operational, will increase NTT’s capacity by over 200% to support the digital backbone of the UK’s financial services, media, and gaming industries. NTT has also invested in duct and fiber to interconnect all its London data centers.
Over the next two years, NTT will increase its available IT load in EMEA by over 40% as it builds 13 new data center buildings across nine markets in six countries to deliver an added 115MW of IT load across 50,000m2. NTT will launch its first data centers in Madrid and Johannesburg as well as adding buildings to Vienna, Zurich, London and across Germany, with expanded data center interconnections.
- APAC:
Jakarta 3 in Indonesia will launch 15MW at Bekasi, approximately 30km from Central Jakarta, by the end of this year. By taking advantage of NTT’s strengths as a network operator, clients will be able to easily connect with IXs and ISPs. Additionally, Cyberjaya 5 in Malaysia started to provide 6.8MW and plan to expand another 6.8MW to the Cyberjaya campus. In Japan, a new data center with 21MW of IT load capacity has been built in Tokyo. In response to strong demand from its clients, NTT is considering further expansion in Bangkok (Thailand), Osaka Metropolitan area (Japan), and Southern Vietnam.
- India:
With Mumbai 8 going live soon, the Chandivali campus, India’s first operational hyperscale data center park, will reach 85MW of IT load. Over the next 18 months, four new hyperscale data center parks will also become operational: two in Navi Mumbai and one each in Chennai and Delhi, adding approximately 133MW of IT load and 50,000m2 of floorspace. Interconnections for 10 data centers across India will also be rolled out in 2021 and submarine cable landing stations are planned in Mumbai and Chennai. This expansion will further consolidate NTT’s number one position in the Indian market.
In addition to the expansion of NTT’s global data center footprint, NTT is currently constructing a "MIST" large-capacity submarine cable connecting Singapore, Malaysia, and India (Mumbai and Chennai).
The MIST cable system will have a total length of 11,000km: a distance which is further than flying from New York, across the US and the Pacific Ocean to land in Tokyo. Construction will complete in mid-2023.
The infrastructure combination of such a significant increase in global data center capacity coupled with NTT’s status as a tier 1 global network service provider, will provide businesses with a secure platform for increasing full-stack ICT service needs.
Global Data Center Interconnect (GDCI), an integrated global network fabric service that delivers a cross regional data center network and private secure connection to major cloud service providers with a single physical port supporting multiple virtual network services, increases this capability to provide a high speed interconnected digital backbone across its global markets. The increased submarine cable system will also help to provide cross-regional data center interconnections.
Masaaki Moribayashi, President and Board Director for NTT Ltd. said, “The pandemic has dramatically changed our way of life. People’s quality of life now fundamentally depends on this infrastructure. In the next 18 months, NTT plans to increase data center operations by 20% to a total of over 600,000m2 (approx. 6.5M ft2) of floorspace in over 20 countries and regions. In addition, NTT will globally expand approximately 30 connection points of GDCI service in our data centers to optimize the enterprise hybrid cloud environment over NTT’s data centers and network services. NTT has already started construction to add 300MW of IT load to its portfolio. With the completion of new data centers, expanded campuses and high capacity networks such as the MIST submarine cable, we are building a connected future that will benefit NTT's clients around the world.”
To contact us about your project and to see the full extent of NTT’s Global Data Center footprint, services and builds visit https://datacenter.hello.global.ntt
1IDC MarketScape: Worldwide Datacenter Colocation and Interconnection Services 2021
-ENDS-
About the Global Data Centers division of NTT Ltd.
Global Data Centers is a division of NTT Ltd. Our global platform is one of the largest in the world. NTT is recognized as a Leader by IDC in the Worldwide Colocation and Interconnection Services MarketScape, spanning more than 20 countries and regions including North America, Europe, Africa, India and APAC. As a neutral operator, we offer access to multiple cloud providers, a large variety of Internet Exchanges and telecommunication network providers including our own IPv6 compliant, tier-one global IP network. Our clients benefit from tailored infrastructure and experience consistent best practices in design and operations across all of our reliable, scalable and customizable data centers.
Visit us at our new website datacenter.hello.global.ntt.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210901005069/en/
Contact information
Media Inquiries:
Beth Sissons
Hotwire for NTT Ltd.
T: +44 7824 144 109
E: beth.sissons@hotwireglobal.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
